Wells Fargo’s ImmunityBio IBRX Stock Holding History

Wells Fargo’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,500	Closed	-$49.9K	–	7438
2026 Q1	$49.9K	Buy	+6,500	New	+$44.5K	﹤0.01%	5455

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo's IBRX Position: Q2 2026 in Review

Wells Fargo increased its ImmunityBio (IBRX) stake by 43% in Q2 2026, buying an estimated $1.68M and bringing the position to 737,031 shares worth $6.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Wells Fargo first reported a position in IBRX in Q3 2015 and has held it in 44 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Wells Fargo held 737,031 shares of ImmunityBio worth $6.45M as of Q2 2026.
Wells Fargo bought 222,310 ImmunityBio shares in Q2 2026, an estimated $1.68M.
ImmunityBio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2601 holding.
Wells Fargo first reported a position in ImmunityBio in Q3 2015 and has held it in 44 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.